Background Immunological phenotypes and differentiation statuses commonly decide the T
cell function and anti-tumor ability. However, little is known about these alterations in CML …

T cell immune surveillance is considered an important host protection process for inhibiting
carcinogenesis. The full capacity of T cell immune surveillance is dependent on T cell …

Background Tumor cells have evolved complex strategies to escape immune surveillance, a
process which involves NK cells and T lymphocytes, and various immunological factors …

Background Myeloid-derived suppressor cell (MDSC)-mediated immune suppression, and
natural killer (NK) and/or T cell-mediated immune responses play important roles in Chronic …

Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib, are effective
forms of therapy for various types of solid cancers and Philadelphia chromosome‑positive …

Tyrosine kinase inhibitors (TKIs) are the current standard treatment in chronic myeloid
leukemia (CML). In addition to the BCR‐ABL target oncoprotein, they also inhibit off‐target …

Increasing evidence suggests that the immune system affects prognosis of chronic myeloid
leukemia (CML), but the detailed immunological composition of the leukemia bone marrow …

Immunological control of residual leukemia cells is thought to occur in patients with chronic
myeloid leukemia (CML) that maintain treatment-free remission (TFR) following tyrosine …

Despite the great success of immune-checkpoint inhibitor (ICI) treatment for multiple
cancers, evidence for the clinical use of ICIs in acute myeloid leukemia (AML) remains …

Therapy with Tyrosine Kinase Inhibitors (TKI) aiming stable deep molecular response is the
gold standard to treat Chronic Myeloid Leukemia (CML). NKT-like cells (CD3+ CD56+) …